Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity
OwnerAlexandre Vamvakidesinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerAlexandre Vamvakidesinventor
Estimating the term…
The present invention involves new and original sigma receptors Ligands: (Mono-or dialkylaminoalkyl)-γ-butyro-lactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl α-[(adamantyl-1)ben-zyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or di-astereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, an-timetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotectve and cytoregenerative activity against the cytodegenerative diseases.
1-8. (canceled)
A method of using sigma(σ) receptor ligands, said method comprising the steps of:
A method of using sigma(σ) receptor ligands, said method comprising the steps of:
A method of using sigma(σ) receptor ligands, said method comprising the steps of:
Dependencies are inferred from the claim text.